Insider · CIK 0001992260

Randhawa Simrat

Reports to the SEC for 1 company · NEW YORK, NY

sec.gov

Transactions

Companies

Filings

CIK

0001992260

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-01	DNTHDianthus Therapeutics, Inc. /DE/M Exercise/Conversion	EVP, Head of R&D	MExercise/Conversion	+7,500 sh	$17.88	+$134K	11,500
2026-09-01	DNTHDianthus Therapeutics, Inc. /DE/M Exercise/Conversion	EVP, Head of R&D	MExercise/Conversion	+6,249 sh	$21.77	+$136K	17,749
2026-09-01	DNTHDianthus Therapeutics, Inc. /DE/M Exercise/Conversion	EVP, Head of R&D	MExercise/Conversion	+9,375 sh	$22.07	+$207K	27,124
2026-09-01	DNTHDianthus Therapeutics, Inc. /DE/S Sale	EVP, Head of R&D	SSale	−2,600 sh	$105.19	−$273K	24,524
2026-09-01	DNTHDianthus Therapeutics, Inc. /DE/S Sale	EVP, Head of R&D	SSale	−7,215 sh	$106.25	−$767K	17,309
2026-09-01	DNTHDianthus Therapeutics, Inc. /DE/S Sale	EVP, Head of R&D	SSale	−13.3K sh	$106.74	−$1.42M	4,000
2026-09-01	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)M Exercise/Conversion	EVP, Head of R&D	MExercise/Conversion	−7,500 sh	—	—	56,776
2026-09-01	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)M Exercise/Conversion	EVP, Head of R&D	MExercise/Conversion	−6,249 sh	—	—	41,676
2026-09-01	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)M Exercise/Conversion	EVP, Head of R&D	MExercise/Conversion	−9,375 sh	—	—	87,500
2026-06-01	DNTHDianthus Therapeutics, Inc. /DE/M Exercise/Conversion	EVP, Head of R&D	MExercise/Conversion	+3,998 sh	$8.44	+$33.7K	7,998
2026-06-01	DNTHDianthus Therapeutics, Inc. /DE/M Exercise/Conversion	EVP, Head of R&D	MExercise/Conversion	+6,908 sh	$17.88	+$124K	14,906
2026-06-01	DNTHDianthus Therapeutics, Inc. /DE/M Exercise/Conversion	EVP, Head of R&D	MExercise/Conversion	+6,249 sh	$21.77	+$136K	21,155
2026-06-01	DNTHDianthus Therapeutics, Inc. /DE/M Exercise/Conversion	EVP, Head of R&D	MExercise/Conversion	+9,375 sh	$22.07	+$207K	30,530
2026-06-01	DNTHDianthus Therapeutics, Inc. /DE/S Sale	EVP, Head of R&D	SSale	−5,428 sh	$89.72	−$487K	25,102
2026-06-01	DNTHDianthus Therapeutics, Inc. /DE/S Sale	EVP, Head of R&D	SSale	−16.9K sh	$90.72	−$1.54M	8,159
2026-06-01	DNTHDianthus Therapeutics, Inc. /DE/S Sale	EVP, Head of R&D	SSale	−4,159 sh	$91.37	−$380K	4,000
2026-06-01	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)M Exercise/Conversion	EVP, Head of R&D	MExercise/Conversion	−3,998 sh	—	—	0
2026-06-01	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)M Exercise/Conversion	EVP, Head of R&D	MExercise/Conversion	−6,908 sh	—	—	64,276
2026-06-01	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)M Exercise/Conversion	EVP, Head of R&D	MExercise/Conversion	−6,249 sh	—	—	47,925
2026-06-01	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)M Exercise/Conversion	EVP, Head of R&D	MExercise/Conversion	−9,375 sh	—	—	96,875
2026-03-12	DNTHDianthus Therapeutics, Inc. /DE/M Exercise/Conversion	EVP, Head of R&D	MExercise/Conversion	+7,998 sh	$8.44	+$67.5K	7,998
2026-03-12	DNTHDianthus Therapeutics, Inc. /DE/M Exercise/Conversion	EVP, Head of R&D	MExercise/Conversion	+5,000 sh	$17.88	+$89.4K	12,998
2026-03-12	DNTHDianthus Therapeutics, Inc. /DE/M Exercise/Conversion	EVP, Head of R&D	MExercise/Conversion	+8,332 sh	$21.77	+$181K	21,330
2026-03-12	DNTHDianthus Therapeutics, Inc. /DE/M Exercise/Conversion	EVP, Head of R&D	MExercise/Conversion	+12.5K sh	$22.07	+$276K	33,830
2026-03-12	DNTHDianthus Therapeutics, Inc. /DE/S Sale	EVP, Head of R&D	SSale	−33.8K sh	$81.48	−$2.76M	0
2026-03-12	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)M Exercise/Conversion	EVP, Head of R&D	MExercise/Conversion	−7,998 sh	—	—	3,998
2026-03-12	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)M Exercise/Conversion	EVP, Head of R&D	MExercise/Conversion	−5,000 sh	—	—	71,184
2026-03-12	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)M Exercise/Conversion	EVP, Head of R&D	MExercise/Conversion	−8,332 sh	—	—	54,174
2026-03-12	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)M Exercise/Conversion	EVP, Head of R&D	MExercise/Conversion	−12.5K sh	—	—	106,250
2026-02-03	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)A Award	EVP, Head of R&D	AAward	+150K sh	—	—	150,000
2025-11-14	DNTHDianthus Therapeutics, Inc. /DE/M Exercise/Conversion	EVP, Head of R&D	MExercise/Conversion	+40.3K sh	$17.88	+$720K	44,287
2025-11-14	DNTHDianthus Therapeutics, Inc. /DE/M Exercise/Conversion	EVP, Head of R&D	MExercise/Conversion	+37.5K sh	$21.77	+$816K	81,781
2025-11-14	DNTHDianthus Therapeutics, Inc. /DE/M Exercise/Conversion	EVP, Head of R&D	MExercise/Conversion	+31.3K sh	$22.07	+$690K	113,031
2025-11-14	DNTHDianthus Therapeutics, Inc. /DE/S Sale	EVP, Head of R&D	SSale	−109K sh	$38.14	−$4.16M	4,000
2025-11-14	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)M Exercise/Conversion	EVP, Head of R&D	MExercise/Conversion	−40.3K sh	—	—	76,184
2025-11-14	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)M Exercise/Conversion	EVP, Head of R&D	MExercise/Conversion	−37.5K sh	—	—	62,506
2025-11-14	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)M Exercise/Conversion	EVP, Head of R&D	MExercise/Conversion	−31.3K sh	—	—	118,750
2025-11-13	DNTHDianthus Therapeutics, Inc. /DE/M Exercise/Conversion	EVP, Head of R&D	MExercise/Conversion	+84K sh	$8.44	+$709K	87,978
2025-11-13	DNTHDianthus Therapeutics, Inc. /DE/M Exercise/Conversion	EVP, Head of R&D	MExercise/Conversion	+3,529 sh	$17.88	+$63.1K	91,507
2025-11-13	DNTHDianthus Therapeutics, Inc. /DE/S Sale	EVP, Head of R&D	SSale	−26.2K sh	$35.80	−$937K	65,341
2025-11-13	DNTHDianthus Therapeutics, Inc. /DE/S Sale	EVP, Head of R&D	SSale	−42.8K sh	$37.04	−$1.58M	22,576
2025-11-13	DNTHDianthus Therapeutics, Inc. /DE/S Sale	EVP, Head of R&D	SSale	−18.6K sh	$37.72	−$701K	4,000
2025-11-13	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)M Exercise/Conversion	EVP, Head of R&D	MExercise/Conversion	−84K sh	—	—	11,996
2025-11-13	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)M Exercise/Conversion	EVP, Head of R&D	MExercise/Conversion	−3,529 sh	—	—	116,471
2025-09-23	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)A Award	EVP, Head of R&D	AAward	+60K sh	—	—	60,000
2025-02-03	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)A Award	EVP, Head of R&D	AAward	+150K sh	—	—	150,000
2024-05-23	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)A Award	EVP, Head of R&D	AAward	+100K sh	—	—	100,000
2024-01-24	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)A Award	EVP, Head of R&D	AAward	+120K sh	—	—	120,000
2023-09-22	DNTHDianthus Therapeutics, Inc. /DE/P Purchase	EVP, Head of R&D	PPurchase	+2,000 sh	$13.20	+$26.4K	4,000
2023-09-21	DNTHDianthus Therapeutics, Inc. /DE/P Purchase	EVP, Head of R&D	PPurchase	+2,000 sh	$13.20	+$26.4K	2,000

Recent filings

Accepted (ET)
Sep 34
Randhawa Simrat0001992260-26-000009
SEC(opens sec.gov)
Jun 24
Randhawa Simrat0001992260-26-000006
SEC(opens sec.gov)

Companies

Dianthus Therapeutics, Inc. /DE/EVP, Head of R&DDNTH

Address

C/O DIANTHUS THERAPEUTICS, INC. 7 TIMES SQUARE, 43RD FLOOR

NEW YORK, NY, 10036